Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 499 across all filing types
Latest filing 2023-09-11 Major Shareholding Noti…
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding, specifically a 'Sell' transaction by Avanza Bank Holding AB for Avanza Pension, resulting in a new total holding percentage (4.97296%) and share count (2,631,098). The text explicitly mentions 'Reason for major shareholding notification' and discusses crossing a threshold ('Flaggning sker för passerat tröskelvärde'). This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the code MRQ.
2023-09-11 English
Dr. Hitto Kaufmann utsedd till Chief Scientific Officer för Hansa Biopharma
Board/Management Information Classification · 100% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces the appointment of Dr. Hitto Kaufmann as the new Chief Scientific Officer (CSO) for Hansa Biopharma, effective December 1, 2023. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition for Board/Management Information (MANG). It is not an Annual Report (10-K), Earnings Release (ER), or a Call Transcript (CT). It is a specific personnel announcement.
2023-09-01 Swedish
Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma
Board/Management Information Classification · 99% confidence The document is explicitly titled "PRESS RELEASE" and announces the appointment of a new Chief Scientific Officer (CSO), Dr. Hitto Kaufmann, effective December 1, 2023. This type of announcement concerns a change in senior management/board composition. Reviewing the definitions, the category 'Board/Management Information (Code: MANG)' specifically covers 'Announcement of changes in the company's board of directors or senior management.' This is a direct match.
2023-09-01 English
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding and voting rights for Hansa Biopharma AB, specifically noting that a threshold has been crossed ('Flaggning sker för passerat tröskelvärde beträffande det aggregerade innehavet'). It lists the 'Before the transaction' and 'After the transaction' holdings, including the number of shares and resulting percentage of voting rights. This type of filing, which reports changes in significant share ownership crossing predefined thresholds, directly corresponds to the Major Shareholding Notification category. Filing Type Code: MRQ (Major Shareholding Notification).
2023-08-25 English
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage by Avanza Bank Holding AB for its pension subsidiary, specifically noting a 'Reason for major shareholding notification Sell' and providing exact share quantities and resulting percentages. This structure, focusing on changes in ownership that cross specific thresholds (implied by the term 'Flaggning sker för passerat tröskelvärde'), directly corresponds to the definition of a Major Shareholding Notification. The filing type code for this is MRQ.
2023-08-24 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document details a change in shareholding and voting rights for Hansa Biopharma AB, specifically reporting that Avanza Bank Holding AB has crossed a threshold ('Flaggning sker för passerat tröskelvärde'). It lists the number of shares and the resulting percentage of voting rights (5.00346%). This type of filing, which reports changes in significant share ownership levels crossing predefined thresholds, directly corresponds to the Major Shareholding Notification category. Code mapping: Major Shareholding Notification maps to 'MRQ'. The document length is short (3228 chars), but it is a complete report of a transaction/holding change, not an announcement *about* a report, so RPA/RNS is not the primary classification.
2023-08-23 Swedish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.